30 results about "Norethisterone" patented technology

A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 15 mcg of ethinyl estradiol for about 7 to about 14 days; a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 25 mcg of ethinyl estradiol for about 14 to about 22 days; a Phase III composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 15 to about 35 mcg of ethinyl estradiol for about 20 to about 31 days; and an optional Phase IV composition containing (i) an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol, or (ii) a placebo or a non-steroidal component, or (iii) a combination of (i) and (ii), for about 2 to about 8 days. The ethinyl estradiol equivalent amount of estrogen in each of the successive Phases II and III is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in the immediately-preceding phase.

A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of said hormone.

The present invention discloses a method of detecting norethisterone and a special enzyme linked immunosorbent kit thereof. The enzyme linked immunosorbent kit which is used for detecting the norethisterone comprises norethisterone haptens and specific antibodies of the norethisterone; and the specific antibodies are polyclonal antibodies or monoclonal antibodies of the norethisterone. The kit adopts the high specificity monoclonal antibodies of the norethisterone, which guarantees the reliability of detection results, and the experimental results show that the kit has the characteristics of high specificity, high sensitivity, high precision, high accuracy and the like; and the main reagents of the kit all adopt the form of working liquid, the operation is convenient, and the cost is low.

The invention relates to a method for removing norgestrel, norethisterone enanthate and norethindrone in waste water of a pharmaceutical factory. 1-vinyl-1-methyl-2,4-2(c-1-ene-2-base)cyclohexane, tetradecanoic acid-1-methyl ethyl ester, hydroxysuccinic acid, sodium pentahydyoxycaproate, argininyl-fructoyl-glucose, 5-allylguaiacol, 1 hydrogen-tetrazolium-1-acetic acid, (2R, 3R)-3,5,7-trihydroxy-2-(3,4,5-3 hydroxy phenyl) benzodihydropyran-4-ketone, alpha-naphthol-8-sulfonic acid, nitrilotrimethylene triphosphonic acid, 3-[10,10-dimethyl-9(10H)-anthracene subunits]-N, N-dimethyl propyl amine hydrochloride, beta-caryophyllene, alchlor, arginine and microcrystalline cellulose are sequentially added into the waste water in three steps. According to the method, the complexing ability with target materials is high, and the removing rate can reach 99.9 percent.

The invention relates to a compound estradiol valerate tablet and its preparation process, wherein the active constituents of the tablet include oestradiol valerate and norethisterone, and at least include a crumbling agent, a soluble deflocculating agent with binding property, a binding agent and a lubricating agent. The tablet has rather good bioavailability in vivo and increased dissolving degree externally.

A synthetic method for tibolone, specifically comprising the following steps: 1) acetylenylation reaction: acidic decarboxylation (I) toluene solution, feed acetylene gas to the raw material to react to obtain norethindrone (II); 2) acylation reaction, Step 1) Add acetic anhydride and acid-binding agent to the obtained norethindrone (II), add acetyl chloride dropwise under control at room temperature, and stir the reaction for 6 hours until the raw materials are completely reacted to obtain the acylate (III); 3) debromination reaction, the acyl compound reaction to obtain norethindrone 4,6-diene acetate (V); 4) methylation reaction, norethindrone 4,6-diene acetate (V), add ether solvent, and cool to -10~30°C , drop methylation reagent, control the temperature at 0-5°C and stir the reaction until the raw materials react completely to obtain 7α-norethindrone methyl acetate (VI); 5) transposition reaction, 7α-norethindrone methyl acetate (VI) React to get transposition (VII) wet product; 6) hydrolysis reaction, translocation (VII) reaction to get tibolone.

The present invention discloses a method of detecting norethisterone and a special enzyme linked immunosorbent kit thereof. The enzyme linked immunosorbent kit which is used for detecting the norethisterone comprises norethisterone haptens and specific antibodies of the norethisterone; and the specific antibodies are polyclonal antibodies or monoclonal antibodies of the norethisterone. The kit adopts the high specificity monoclonal antibodies of the norethisterone, which guarantees the reliability of detection results, and the experimental results show that the kit has the characteristics of high specificity, high sensitivity, high precision, high accuracy and the like; and the main reagents of the kit all adopt the form of working liquid, the operation is convenient, and the cost is low.

The invention discloses an analysis method for various active ingredients in oral contraceptive pill placebo tablets. Firstly, put the placebo tablet to be tested into a measuring bottle, then add water to make it disintegrate, and then add an organic solvent (acetonitrile) for ultrasonic extraction. Then use acetonitrile to set the volume to scale, filter and get the filtrate as the test sample analysis; adopt liquid chromatography to analyze the test sample, start the chromatographic acquisition computer system to collect data; get norethindrone acetate, desogestrel and ethinyl estradiol contrast For the product, prepare the reference solution with a mixed solution of acetonitrile and water, and carry out liquid chromatography analysis simultaneously to check whether the placebo tablet contains multiple active ingredients. The invention has the advantages of strong specificity, rapid analysis, strong anti-interference and high sensitivity, and solves the problem that multiple active ingredients in oral contraceptive placebo tablets need to be repeatedly measured.

The invention discloses a stable pharmaceutical composition containing ethinylestradiol and norethindrone acetate. Vitamin E is added, so that the stability of ethinylestradiol is improved; and by using a specific amount of vitamin E, the production of related substances of ethinylestradiol and norethindrone acetate is controlled at the same time, and the overall stability of the compound preparation is improved.

The invention discloses a preparation method of 19 hydroxylated cortodoxone derivative and 19-hydroxy-4-androsten-3,17-dione, and belongs to the fields of organic synthesis and pharmacy. The preparation method provided by the invention comprises the following steps: using 19-hydroxy-cotondoxone as a raw material; performing at least one of the following reactions among 19-hydroxy-cotondoxone underrespective actions of hydrogen peroxide, trimethyl iodosilane, palladium on activated carbon, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, iodobenzene oxide, sodium borohydride, sodium periodate and other reagents: performing structural modification on a ring A and a ring B of 19 hydroxylated cortodoxone, substituting 17, 21 and / or 19 hydroxyl with substituents, and excising a side chain of 19 hydroxylated cortodoxone. The preparation method provided by the invention greatly improves preparation efficiency of an essential intermediate 19-hydroxy-4-androsten-3,17-dione for synthesizing norethindrone contraceptives, and reduces production costs of medicines.

The present invention relates to a method for analyzing impurities of steroidal compounds, in particular to a method for detecting and analyzing impurities of norethindrone derivatives and their intermediates, comprising: (1) choosing octadecylsilane bonded silica gel as filler The chromatographic column; the gradient elution of the mobile phase, the composition of the mobile phase is water, methanol and acetonitrile; the detection wavelength is 230 ~ 254nm; (2) take the test sample norethindrone derivative or its intermediate amount, accurately weigh the methanol Dissolve and dilute to a certain concentration of the sample solution, shake it up, inject the sample, perform high-performance liquid chromatography analysis at an appropriate flow rate and column temperature, and record the chromatogram. The invention can quickly and accurately realize the impurity analysis of norethindrone derivatives, especially for the impurity analysis of norethindrone enanthate, and can be used for the impurity analysis of norethindrone derivative intermediates, and can effectively track the impurities produced in the synthesis process. Impurities.

Provided herein is a female hormone-containing patch wherein an active ingredient is highly soluble in a pressure-sensitive adhesive layer and the active ingredient is not adsorbed to a backing, and the patch per se can follow the irregularities on the skin surface or body movements. The patch is an external patch containing, as a female hormone, a follicular hormone estradiol and / or its derivative or a progestational hormone norethisterone and / or its derivative. The external patch comprises an acrylic pressure-sensitive adhesive containing 0.01 to 1% by weight of an isocyanate-based crosslinking agent as an essential ingredient.

A stable pharmaceutical composition comprising ethinyl estradiol and norethindrone acetate, the stability of ethinyl estradiol is improved by adding vitamin E; and by using specific amount of vitamin E, the stability of ethinyl estradiol and norethindrone acetate is controlled The production of related substances improves the overall stability of the compound preparation.